Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04531709 · ClinicalTrials.gov registry record
Financial Toxicity and Quality of Life in Patients With TGCT
A clinical trial, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- 24
- Enrollment target
NCT04531709: Completed study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT04531709 is a clinical trial that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04531709 has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.
Interventions
- OTHER Comprehensive Score for financial toxicity (COST)
- OTHER Functional Assessment of Cancer Therapy: General (FACT-G)
- OTHER EORTC QLQ C-30
- OTHER EORTC QLQ-TC26.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2025-02-04 |
What the finished NCT04531709 record still lists
NCT04531709 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Comprehensive Score for financial toxicity (COST) is the first listed.
NCT04531709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04531709 about?
NCT04531709 is a clinical study titled "Financial Toxicity and Quality of Life in Patients With TGCT". This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of...
What is the current status of trial NCT04531709?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2023-03-01. Estimated completion is 2025-02-04.
What interventions are being tested in trial NCT04531709?
The interventions under investigation include: Comprehensive Score for financial toxicity (COST) (OTHER), Functional Assessment of Cancer Therapy: General (FACT-G) (OTHER), EORTC QLQ C-30 (OTHER), EORTC QLQ-TC26. (OTHER).
Who is sponsoring clinical trial NCT04531709?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI